Oppenheimer Upgrades Milestone to Outperform on 'Best-Case' FDA Outcome
July 29, 2020 at 09:31 AM EDT
Oppenheimer analyst Leland Gershell upgraded Milestone Pharmaceuticals to Outperform from Perform with an $18 price target.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.